PainReform Ltd (NAS:PRFX)
$ 2.92 -0.08 (-2.67%) Market Cap: 1.77 Mil Enterprise Value: -952,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 28/100

PainReform Ltd at Benzinga All Access Event (Virtual) Transcript

Dec 16, 2021 / 03:00PM GMT
Release Date Price: $340.8 (-8.97%)
Spencer Israel
Benzinga - Media

Let's bring on Ilan Hadar right now, the CEO of PainReform. Mr. Hadar, how we doing today?

Ilan Hadar
PainReform Ltd. - CEO

I'm great, Spencer. Nice to meet you, and great to be here. How are you today?

Spencer Israel
Benzinga - Media

I'm doing fantastic. I feel like it should be Friday. It's not, but it's Friday in my head, and that's all that matters. So we'll start with this -- PainReform, tell us what you do, and then we'll go from there.

Ilan Hadar
PainReform Ltd. - CEO

PainReform is Israeli company founded back in 2008. We are doing our post-operative pain management drugs right now. We are working on our leading candidate to become post-operative pain management. It's PRF-110. It's a drug that's supposed to give relief of pain up to 72 hours post-operation.

Questions & Answers

Spencer Israel
Benzinga - Media

What is the unmet need here? Obviously there are many operations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot